Journal
ONCOIMMUNOLOGY
Volume 5, Issue 6, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2016.1163462
Keywords
Cancer; combined therapy; cytokine; immunotherapy; interleukin-2
Categories
Funding
- National Natural Science Foundation of China [81372392, 81201707]
- key project of Shanghai Municipal Commission of Health and Family Planning [2013zyjb0401]
- Outstanding Yong Doctor Program of Shanghai Municipal Commission of Health and Family Planning [XYQ2013097]
- Science and Technology Commission of Shanghai Municipality [12ZR1426000]
Ask authors/readers for more resources
Interleukin-2 (IL-2) is one of the key cytokines with pleiotropic effects on immune system. It has been approved for the treatment of metastatic renal cell carcinoma and metastatic melanoma. Recent progress has been made in our understanding of IL-2 in regulating lymphocytes that has led to exciting new directions for cancer immunotherapy. While improved IL-2 formulations might be used as monotherapies, their combination with other anticancer immunotherapies, such as adoptive cell transfer regimens, antigen-specific vaccination, and blockade of immune checkpoint inhibitory molecules, for example cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) mono-antibodies, would held the promise of treating metastatic cancer. Despite the comprehensive studies of IL-2 on immune system have established the application of IL-2 for cancer immunotherapy, a number of poignant obstacles remain for future research. In the present review, we will focus on the key biological features of IL-2, current applications, limitations, and future directions of IL-2 in cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available